Juvenile toxicity assessment of d,l-methylphenidate in rats
✍ Scribed by David A. Beckman; Marilynn Schneider; Maureen Youreneff; Francis L.S. Tse
- Publisher
- John Wiley and Sons
- Year
- 2008
- Tongue
- English
- Weight
- 174 KB
- Volume
- 83
- Category
- Article
- ISSN
- 1542-9733
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
BACKGROUND: The oral administration of d,l‐methylphenidate (MPH) was designed to encompass the major part of postnatal development in the rat and to evaluate potential chronic effects. METHODS: Wistar Hannover rats were cross‐fostered on postpartum day 0 (day of birth) and were administered MPH at doses of 5, 50, and 100 mg/kg/day (mpkd) on postpartum days 7 to 70. Clinical signs, body weight, food consumption, developmental, behavioral, clinical/anatomic pathology, toxicokinetic, and fertility evaluations were conducted. RESULTS: MPH‐related effects on clinical signs, body weight, and behavior tests were noted. Increased locomotor activity and cage biting/chewing occurred at ≥5 mpkd (females) and ≥50 mpkd (males) and were absent after dosing ceased. Body weight parameters were decreased at ≥50 mpkd and were comparable to controls at 5 weeks' recovery. Open field motor activity tests conducted 2 weeks after dosing ceased revealed decreased peripheral beam breaks at ≥50 mpkd. Passive avoidance tests conducted 3 weeks after dosing ceased indicated decreased females reaching learning criterion at 100 mpkd. This is considered of nominal significance as there were no effects in the water maze test or retention in passive avoidance test. After multiple doses, females exhibited higher exposures than males and exposures were reduced in all groups in comparison to those after a single dose. CONCLUSIONS: These results suggest that MPH can produce enduring behavioral effects in rats. The no‐toxicologic‐effect‐level was 5 mpkd, associated with AUC~(0–24 h)~ racemate values in males and females, respectively, of 101 and 153 ng.h/mL after chronic dosing. Birth Defects Res (Part B) © 2008 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
## Abstract **BACKGROUND:** D,L‐__threo__‐Methylphenidate (D,L‐MPH) is marketed currently for attention deficit hyperactivity disorder in children. D‐__threo__‐methylphenidate (dexmethylphenidate; D‐MPH) is a refined formulation of D,L‐methylphenidate containing only the active enantiomer and was r
Ritalin or methylphenidate (MPH) is prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The present report describes the determination of plasma concentrations of D-threo- and L-threo-enantiomers of MPH in toxicokinetic (TK) studies in pregnant Wistar Hann
## Abstract Ritalin^®^ or methylphenidate (MPH) is often prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. The therapeutic activity of MPH is principally due to d‐__threo__‐[2__R__,2′__R__]‐MPH. Hence, in order to establish a kinetic relationship between
## Abstract **BACKGROUND:** Lasofoxifene is a nonsteroidal selective estrogen receptor modulator (SERM) with greater than 100‐fold selectivity against all other steroid receptors and is a potentially superior treatment for postmenopausal osteoporosis. The purpose of this study was to evaluate the e